Catalent Inc (CTLT)
Gross profit margin
Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | ||
---|---|---|---|---|---|---|
Gross profit | US$ in thousands | 953,000 | 1,040,000 | 1,614,000 | 1,352,000 | 983,000 |
Revenue | US$ in thousands | 4,381,000 | 4,263,000 | 4,802,000 | 3,998,000 | 3,094,000 |
Gross profit margin | 21.75% | 24.40% | 33.61% | 33.82% | 31.77% |
June 30, 2024 calculation
Gross profit margin = Gross profit ÷ Revenue
= $953,000K ÷ $4,381,000K
= 21.75%
Catalent Inc's gross profit margin has shown a declining trend over the past five years, decreasing from 31.77% in 2020 to 21.75% in 2024. This indicates that the company is generating less gross profit relative to its revenue in recent years. A lower gross profit margin could be attributed to various factors such as increasing production costs, pricing pressure, or inefficiencies in production processes. It is essential for Catalent Inc to closely monitor and address the drivers behind this declining trend to maintain profitability and competitiveness in the industry.
Peer comparison
Jun 30, 2024
Company name
Symbol
Gross profit margin
Catalent Inc
CTLT
21.75%
Abbott Laboratories
ABT
20.40%
AbbVie Inc
ABBV
16.39%
Alkermes Plc
ALKS
42.73%
Amphastar P
AMPH
51.08%
ANI Pharmaceuticals Inc
ANIP
11.30%
Arcus Biosciences Inc
RCUS
41.86%
Biomarin Pharmaceutical Inc
BMRN
79.61%
Bristol-Myers Squibb Company
BMY
34.23%
Catalyst Pharmaceuticals Inc
CPRX
45.19%
Collegium Pharmaceutical Inc
COLL
70.92%